Cannabis Compounds Show Promise Against Cancer and Viral Disease—But the Evidence Is Still Largely Preclinical
This cannabis compounds medical evidence review summarizes recent research on cannabinoids in cancer and viral disease. While promising preclinical data exist, clinical evidence remains limited. The review clarifies where cannabis-derived therapies have…
Cannabis in Pregnancy: What the Science Actually Shows—and What It Doesn’t
This prenatal cannabis exposure neurodevelopment review synthesizes current evidence on cannabis use during pregnancy and its potential impact on offspring brain development. While animal studies provide mechanistic insights, human data remain…
Cannabis Use in Older Surgical Patients: What Anesthesiologists Need to Know
Cannabis anesthesia older adults is an emerging concern as use rises among surgical patients over 65. This review highlights perioperative risks including respiratory and cardiovascular effects. Understanding cannabis anesthesia older adults interactions…
Medical Cannabis Evidence Map: Broad Promise, Variable Proof
The 2024 medical cannabis evidence map synthesizes 194 systematic reviews across 71 health outcomes, focusing on high-quality evidence. It highlights positive or potentially positive effects for pain, seizures, anxiety, and more. This map guides…
Cannabis and the Heart and Vessels: What the Science Actually Says
This 2024 narrative review explores cannabinoid involvement in atherosclerosis and other vascular diseases, highlighting both therapeutic promise and evidentiary gaps. The endocannabinoid system plays a complex role in vascular biology through multiple…
Cannabinoids Show Short-Term Promise for Sleep Apnea, But Evidence Remains Too Thin for Clinical Use
A cannabinoids sleep apnea systematic review shows mostly positive short-term outcomes, including reduced apnea hypopnea index and improved daytime sleepiness. However, adverse events occurred in 70-80% of participants, raising safety concerns. The…
Medical Cannabis for Arthritis Pain: What the Evidence Really Shows
Despite promising preclinical and observational evidence, medical cannabis rheumatic pain treatment lacks high-quality clinical trials. This 2024 review highlights the gap between patient use and clinical evidence. Clinicians should engage patients…
CBD and Anxiety: Promising Signal, Weak Evidence Base
The cbd anxiety clinical trials 2024 review reveals most studies are exploratory with varied designs and small samples. Evidence supporting CBD for anxiety disorders remains weak and inconclusive. This review highlights the urgent need for robust…
Opioids and Cannabinoids for Neurologic Pain: What Neurologists Need to Know in 2024
This 2024 CME review focuses on opioid therapy neurologic pain, synthesizing current evidence and guidelines for neurologists. It highlights risks of abrupt opioid tapering and the investigational role of cannabinoids. The review supports a cautious,…
CB2 Receptors in the Brain: A Promising but Unproven Anti-Inflammatory Target
CB2 receptor neuroinflammation is a promising target in neurodegenerative diseases such as Alzheimer's and Parkinson's. Preclinical studies show CB2 activation reduces brain inflammation and protects neurons. However, clinical evidence for CB2 receptor…